204 results
Page 3 of 11
8-K
EX-99.2
0hr 4k306j80jaimj
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
424B5
1c8j1vwetesxx
3 Dec 21
Prospectus supplement for primary offering
4:06pm
424B5
97cnjev
30 Nov 21
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
xk4hclj0h4qn9uahyc8
30 Nov 21
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
EX-99.1
vmufafcgj
29 Oct 21
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
6:43am
424B5
0k4d6
12 Aug 21
Prospectus supplement for primary offering
10:11am
8-K
EX-99.1
9ers9s xiv7
30 Jul 21
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
6:36am
8-K
EX-99.1
zcieh40v573tzj8j5
10 May 21
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
6:36am
8-K
EX-99.1
kafbgv2 34
12 Feb 21
Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End
6:37am
8-K
EX-10.1
xj3hp
18 Dec 20
Entry into a Material Definitive Agreement
5:19pm
424B5
4n7uhs864xfpm2lcbas6
18 Dec 20
Prospectus supplement for primary offering
5:16pm
S-3ASR
72f7torhmg
18 Dec 20
Automatic shelf registration
4:45pm
8-K
EX-99.1
6li xzjkkerh
18 Dec 20
Other Events
4:16pm
8-K
EX-99.1
5yd0h94s0n71dy4gkm9
7 Dec 20
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
8:02am